Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease

Mycoses

Volumn 54, Issue 6, 2011, Pages

  Cornely, Oliver A ^a   Marty, Francisco M ^b   Stucker, Flavie ^c   Pappas, Peter G ^d   Ullmann, Andrew J ^e  

^a UNIVERSITY OF COLOGNE   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Astellas Pharma Global Development   (Netherlands)

^d University of Alabama at Birmingham   (United States)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Candidaemia; Candidiasis; Malignancy; Mycamine

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; MICAFUNGIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANDIDIASIS; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEOPLASM; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ECHINOCANDINS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LIPOPEPTIDES; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

CANDIDA;

EID: 80053959089     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02045.x     Document Type: Article

References (24)

1. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238-45.
2. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006; 162: 1-15.
3. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
4. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-22.
5. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
6. Bodey GP, Mardani M, Hanna HA et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-5.
7. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 2493-9.
8. White MH, Bowden RA, Sandler ES et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296-302.
9. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-7.
10. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155-63.
11. Ullmann AJ, Sanz MA, Tramarin A et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006; 43: e29-38.
12. Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
13. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
14. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
15. Gibbs WJ, Drew RH, Perfect JR. Liposomal amphotericin B: clinical experience and perspectives. Expert Rev Anti Infect Ther 2005; 3: 167-81.
16. Cornely OA, Vehreschild JJ, Ullmann AJ. Is there a role for polyenes in treating invasive mycoses? Curr Opin Infect Dis 2006; 19: 565-70.
17. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
18. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
19. Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27: 820-6.
20. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
21. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
22. Astellas Pharma GmbH. Mycamine: summary of product characteristics. Astellas Pharma GmbH. URL [accessed on 10 February 2011].
23. Astellas Pharma US Inc. Mycamine® (micafungin sodium) for injection: prescribing information. Astellas Pharma US Inc., January 2008. URL [accessed on 10 February 2011].
24. Cornely OA, Pappas PG, Young JH et al. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. Expert Opin Drug Saf 2011; 10: 171-83.